NantHealth, Inc.
NHIQ · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.01 | -0.00 |
| FCF Yield | -119.26% | -186.36% | -50.85% | -33.29% |
| EV / EBITDA | -53.76 | -28.74 | -55.68 | -16.02 |
| Quality | ||||
| ROIC | -9.08% | -7.12% | -9.23% | -10.13% |
| Gross Margin | 56.61% | 66.93% | 62.32% | 57.80% |
| Cash Conversion Ratio | 0.51 | 0.36 | 0.54 | 0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.48% | -0.59% | -1.66% | -2.89% |
| Free Cash Flow Growth | -6.48% | 8.39% | 16.30% | -48.14% |
| Safety | ||||
| Net Debt / EBITDA | -52.51 | -28.35 | -52.71 | -14.48 |
| Interest Coverage | -2.16 | -1.82 | -2.94 | -3.52 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -75.26 | -66.35 | -98.70 | -87.37 |